Treatment of human brucellosis with rifampin plus minocycline
- Authors: Cascio, A.; Scarlata, F.; Giordano, S.; Antinori, S.; Colomba, C.; TITONE LANZA DI SCALEA, L.
- Publication year: 2003
- Type: Articolo in rivista (Articolo in rivista)
- Key words: brucellosis
- OA Link: http://hdl.handle.net/10447/63451
Abstract
In order to evaluate the efficacy and tolerability of a high intravenous dose of rifampin plus oral minocycline (administered daily for 3 weeks) for the treatment of acute brucellosis, we retrospectively reviewed the outcome of 239 consecutive patients (135 adults and 104 children) diagnosed and treated over a 17-year period in Italy. The combination used resulted in 100% response and a relapse rate lower than 2%. Fifty-two (30 adults and 22 children) (29.8%) complained of mild adverse effects including an increase in aspartate aminotransferase (>250 IU) observed in 12 cases and considered related to rifampin and in 11 cases a reversible hyperpigmentation of the tongue attributed to minocycline. A randomized prospective comparative study should be performed to confirm our encouraging results